慢性膵炎（CP）の世界市場レポート 2025年

慢性膵炎（CP）市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.4％で67億2,000万米ドルに成長します。予測期間における成長の背景には、高齢者人口の増加、酵素補充療法に対する需要の増加、早期診断に対する意識の高まり、新興国市場におけるヘルスケアインフラの拡充、新規疼痛管理療法の市場開拓、膵炎治療に関する研究や臨床試験の増加があります。主な動向としては、画像診断における人工知能の利用、低侵襲手術技術の進歩、継続的な健康モニタリングのためのウェアラブルの採用、遺伝子検査のための次世代シーケンシング、疾患進行追跡における機械学習の統合、スマート診断ツールの開発などが挙げられます。

アルコールの消費量の増加は、今後数年間の慢性膵炎市場の成長を促進すると予想されます。アルコール消費には、エタノールを含む飲料の摂取が含まれ、多くの場合、レクリエーション、社会的、文化的な理由によるものであるが、過度の使用は依存症や健康合併症につながる可能性があります。社会的受容の拡大、都市化、ライフスタイルの進化、特に若年層におけるストレス管理習慣などの要因が、アルコール消費の拡大に寄与しています。アルコール誘発性慢性膵炎は、膵細胞の炎症と損傷によって起こり、その結果、線維化、管閉塞、有毒な代謝製品別による長期的な機能障害を引き起こします。例えば、2023年12月、日本のビール・飲料持株会社であるキリンホールディングス株式会社の公開会社によると、2022年の世界のビール総消費量は2021年と比較して約540万キロリットル（633ml瓶約85億本相当）増加し、約1億9,210万キロリットルに達しました。この2.9%の増加は、COVID-19の影響が緩和されたことによるもので、633ml瓶にして約3,035億本に相当します。その結果、アルコール消費の増加が慢性膵炎市場の拡大に拍車をかけています。

慢性膵炎市場の主要企業は、慢性膵炎に伴う膵外分泌機能不全（EPI）に対処するため、酵素補充療法などの技術進歩に投資しています。酵素補充療法は、膵機能が低下した患者の消化をサポートするために膵酵素を経口投与するものです。例えば、2023年7月、米国を拠点とする臨床段階のバイオ医薬品会社であるファースト・ウェーブ・バイオファーマ社は、嚢胞性線維症（CF）と慢性膵炎の患者におけるEPI治療のためのアドルリパーゼの高度な腸内マイクログラニュール送達製剤を評価する第2相SPAN臨床試験の結果を発表しました。アドルリパーゼはヤロウィア・リポリティカ酵母由来の組換えリパーゼ酵素で、EPI患者の消化管内で脂肪分子を分解し、栄養吸収を可能にするよう設計された経口非全身投与生物学的カプセルとして投与されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界慢性膵炎（CP） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の慢性膵炎（CP）市場：成長率分析
• 世界の慢性膵炎（CP）市場の実績：規模と成長, 2019-2024
• 世界の慢性膵炎（CP）市場の予測：規模と成長, 2024-2029, 2034F
• 世界慢性膵炎（CP）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の慢性膵炎（CP）市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 鎮痛剤
• 人工消化酵素
• プロテインサプリメント
• ステロイド
• 抗生物質
• その他の治療法
• 世界の慢性膵炎（CP）市場診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• コンピュータ断層撮影（CT）スキャン
• 磁気共鳴胆道膵管造影検査
• 超音波検査
• その他の診断
• 世界の慢性膵炎（CP）市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• 世界の慢性膵炎（CP）市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• その他のエンドユーザー
• 世界の慢性膵炎（CP）市場鎮痛剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非ステロイド性抗炎症薬（NSAID）
• オピオイド
• 世界の慢性膵炎（CP）市場人工消化酵素の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• パンクレリパーゼ
• パンクレアチン
• 世界の慢性膵炎（CP）市場プロテインサプリメントの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 分岐鎖アミノ酸（BCAA）
• ホエイプロテイン
• 世界の慢性膵炎（CP）市場ステロイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プレドニゾン
• デキサメタゾン
• 世界の慢性膵炎（CP）市場抗生物質の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• シプロフロキサシン
• メトロニダゾール
• 世界の慢性膵炎（CP）市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 内視鏡治療
• 手術

第7章 地域別・国別分析

• 世界の慢性膵炎（CP）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の慢性膵炎（CP）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 慢性膵炎（CP）市場：競合情勢
• 慢性膵炎（CP）市場：企業プロファイル
  • Pfizer Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co Inc Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb
• Abbott Laboratories
• Novartis AG
• GlaxoSmithKline plc
• Baxter
• CSL Behring
• Octapharma AG
• Dr. Reddy's Laboratories
• Nestle Health Science
• Cerata Pharmaceuticals
• Unichem Laboratories Ltd
• LGM Pharma
• Aptalis Pharmaceutical Technologies
• Digestive Care Inc
• Akron Biotech

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 慢性膵炎（CP）市場2029：新たな機会を提供する国
• 慢性膵炎（CP）市場2029：新たな機会を提供するセグメント
• 慢性膵炎（CP）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Chronic pancreatitis (CP) is a persistent, progressive inflammatory disorder of the pancreas that leads to irreversible structural and functional damage. It is characterized by ongoing inflammation, fibrosis (scarring), and the gradual loss of the pancreas's ability to produce digestive enzymes and hormones such as insulin.

The primary treatment options for chronic pancreatitis include analgesics, artificial digestive enzymes, protein supplements, steroids, antibiotics, and others. Analgesics help manage pain, a common symptom of the condition. Diagnosis methods include computed tomography (CT) scans, magnetic resonance cholangiopancreatography, ultrasound sonography, and others. The routes of administration for treatments are oral and parenteral, with end users including hospitals, home care, and other healthcare providers.

The chronic pancreatitis (CP) market research report is one of a series of new reports from The Business Research Company that provides chronic pancreatitis (CP) market statistics, including chronic pancreatitis (CP) industry global market size, regional shares, competitors with a chronic pancreatitis (CP) market share, detailed chronic pancreatitis (CP) market segments, market trends and opportunities, and any further data you may need to thrive in the chronic pancreatitis (CP) industry. This chronic pancreatitis (CP) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chronic pancreatitis (CP) market size has grown strongly in recent years. It will grow from $4.91 billion in 2024 to $5.25 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to the increasing prevalence of alcohol consumption, the rising incidence of smoking, genetic predisposition and family history, growing awareness of pancreatic diseases, the rising cases of diabetes linked to pancreatitis, increasing healthcare spending, and improved access to healthcare services.

The chronic pancreatitis (CP) market size is expected to see strong growth in the next few years. It will grow to $6.72 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to the rising geriatric population, increasing demand for enzyme replacement therapies, growing awareness of early diagnosis, expansion of healthcare infrastructure in emerging markets, development of novel pain management therapies, and increasing research and clinical trials for pancreatitis treatment. Major trends include the use of artificial intelligence in diagnostic imaging, advancements in minimally invasive surgical techniques, the adoption of wearables for continuous health monitoring, next-generation sequencing for genetic testing, integration of machine learning in disease progression tracking, and the development of smart diagnostic tools.

The rising consumption of alcohol is anticipated to drive the growth of the chronic pancreatitis market in the coming years. Alcohol consumption involves the intake of ethanol-containing beverages, often for recreational, social, or cultural reasons, but excessive use can lead to dependency and health complications. Factors such as increasing social acceptance, urbanization, evolving lifestyles, and stress management practices, particularly among younger demographics, contribute to the growing consumption of alcohol. Alcohol-induced chronic pancreatitis occurs due to inflammation and damage to pancreatic cells, resulting in fibrosis, ductal blockages, and long-term dysfunction caused by toxic metabolic byproducts. For example, in December 2023, a publication by Kirin Holdings Company Limited, a Japan-based beer and beverage holding company, reported that total global beer consumption in 2022 increased by approximately 5.4 million kiloliters (equivalent to around 8.5 billion 633ml bottles) compared to 2021, reaching around 192.1 million kiloliters. This 2.9% increase was attributed to the easing of COVID-19's impact, amounting to roughly 303.5 billion 633ml bottles. As a result, the rising consumption of alcohol is fueling the expansion of the chronic pancreatitis market.

Leading companies in the chronic pancreatitis market are investing in technological advancements such as enzyme replacement therapy to address exocrine pancreatic insufficiency (EPI) associated with chronic pancreatitis. Enzyme replacement therapy involves administering oral pancreatic enzymes to support digestion in individuals with impaired pancreatic function. For instance, in July 2023, First Wave BioPharma Inc., a US-based clinical-stage biopharmaceutical company, announced results from the Phase 2 SPAN clinical trial evaluating an advanced enteric microgranule delivery formulation of adrulipase for treating EPI in patients with cystic fibrosis (CF) and chronic pancreatitis. Adrulipase, a recombinant lipase enzyme derived from Yarrowia lipolytica yeast, is administered as an oral, non-systemic biologic capsule designed to break down fat molecules in the digestive tract of EPI patients, enabling nutrient absorption.

In March 2023, CalciMedica Inc., a US-based clinical-stage biopharmaceutical company, merged with Graybug Vision Inc. for an undisclosed amount. This merger, structured as a reverse transaction, strengthens CalciMedica's efforts in developing therapies for life-threatening inflammatory diseases. Graybug Vision Inc. is a US-based clinical-stage biopharmaceutical company focused on advancing treatments for severe inflammatory diseases, including pancreatitis.

Major players in the chronic pancreatitis (CP) market are Pfizer, Johnson & Johnson, Merck & Co Inc, AbbVie Inc, Sanofi, Bristol-Myers Squibb, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Baxter, CSL Behring, Octapharma AG, Dr. Reddy's Laboratories, Nestle Health Science, Cerata Pharmaceuticals, Unichem Laboratories Ltd, LGM Pharma, Aptalis Pharmaceutical Technologies, Digestive Care Inc, and Akron Biotech.

North America was the largest region in the chronic pancreatitis (CP) market in 2024. The regions covered in chronic pancreatitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chronic pancreatitis (CP) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic pancreatitis market consists of revenues earned by entities by providing services such as diagnostic imaging, endoscopic procedures, pain management, nutritional counseling, and telemedicine services for the diagnosis and management of chronic pancreatitis. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic pancreatitis market also includes sales of enzyme replacement therapies, pain management drugs, anti-inflammatory treatments, biologics, stem cell therapies, and surgical interventions, as well as diagnostic tools such as imaging and laboratory tests. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Pancreatitis (CP) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic pancreatitis (cp) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chronic pancreatitis (cp) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic pancreatitis (cp) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Analgesic; Artificial Digestive Enzyme; Protein Supplements; Steroids; Antibiotics; Other Treatments
• 2) By Diagnosis: Computed Tomography (CT) Scan; Magnetic Resonance Cholangiopancreatography; Ultrasound Sonography; Other Diagnosis
• 3) By Route Of Administration: Oral; Parenteral
• 4) By End User: Hospitals; Homecare; Other End Users
• Subsegments:
• 1) By Analgesic: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs); Opioids
• 2) By Artificial Digestive Enzyme: Pancrelipase; Pancreatin
• 3) By Protein Supplements: Branched-Chain Amino Acids (BCAA); Whey Protein
• 4) By Steroids: Prednisone; Dexamethasone
• 5) By Antibiotics: Ciprofloxacin; Metronidazole
• 6) By Other Treatments: Endoscopic Treatment; Surgery
• Companies Mentioned: Pfizer; Johnson & Johnson; Merck & Co Inc; AbbVie Inc; Sanofi
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chronic Pancreatitis (CP) Market Characteristics

3. Chronic Pancreatitis (CP) Market Trends And Strategies

4. Chronic Pancreatitis (CP) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Chronic Pancreatitis (CP) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Chronic Pancreatitis (CP) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Chronic Pancreatitis (CP) Market Growth Rate Analysis
• 5.4. Global Chronic Pancreatitis (CP) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Chronic Pancreatitis (CP) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Chronic Pancreatitis (CP) Total Addressable Market (TAM)

6. Chronic Pancreatitis (CP) Market Segmentation

• 6.1. Global Chronic Pancreatitis (CP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Analgesic
• Artificial Digestive Enzyme
• Protein Supplements
• Steroids
• Antibiotics
• Other Treatments
• 6.2. Global Chronic Pancreatitis (CP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Computed Tomography (CT) Scan
• Magnetic Resonance Cholangiopancreatography
• Ultrasound Sonography
• Other Diagnosis
• 6.3. Global Chronic Pancreatitis (CP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• 6.4. Global Chronic Pancreatitis (CP) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Other End Users
• 6.5. Global Chronic Pancreatitis (CP) Market, Sub-Segmentation Of Analgesic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Opioids
• 6.6. Global Chronic Pancreatitis (CP) Market, Sub-Segmentation Of Artificial Digestive Enzyme, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pancrelipase
• Pancreatin
• 6.7. Global Chronic Pancreatitis (CP) Market, Sub-Segmentation Of Protein Supplements, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Branched-Chain Amino Acids (BCAA)
• Whey Protein
• 6.8. Global Chronic Pancreatitis (CP) Market, Sub-Segmentation Of Steroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prednisone
• Dexamethasone
• 6.9. Global Chronic Pancreatitis (CP) Market, Sub-Segmentation Of Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ciprofloxacin
• Metronidazole
• 6.10. Global Chronic Pancreatitis (CP) Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Endoscopic Treatment
• Surgery

7. Chronic Pancreatitis (CP) Market Regional And Country Analysis

• 7.1. Global Chronic Pancreatitis (CP) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Chronic Pancreatitis (CP) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chronic Pancreatitis (CP) Market

• 8.1. Asia-Pacific Chronic Pancreatitis (CP) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Chronic Pancreatitis (CP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Chronic Pancreatitis (CP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Chronic Pancreatitis (CP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chronic Pancreatitis (CP) Market

• 9.1. China Chronic Pancreatitis (CP) Market Overview
• 9.2. China Chronic Pancreatitis (CP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Chronic Pancreatitis (CP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Chronic Pancreatitis (CP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chronic Pancreatitis (CP) Market

• 10.1. India Chronic Pancreatitis (CP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Chronic Pancreatitis (CP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Chronic Pancreatitis (CP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chronic Pancreatitis (CP) Market

• 11.1. Japan Chronic Pancreatitis (CP) Market Overview
• 11.2. Japan Chronic Pancreatitis (CP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Chronic Pancreatitis (CP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Chronic Pancreatitis (CP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chronic Pancreatitis (CP) Market

• 12.1. Australia Chronic Pancreatitis (CP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Chronic Pancreatitis (CP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Chronic Pancreatitis (CP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chronic Pancreatitis (CP) Market

• 13.1. Indonesia Chronic Pancreatitis (CP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Chronic Pancreatitis (CP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Chronic Pancreatitis (CP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chronic Pancreatitis (CP) Market

• 14.1. South Korea Chronic Pancreatitis (CP) Market Overview
• 14.2. South Korea Chronic Pancreatitis (CP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Chronic Pancreatitis (CP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Chronic Pancreatitis (CP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chronic Pancreatitis (CP) Market

• 15.1. Western Europe Chronic Pancreatitis (CP) Market Overview
• 15.2. Western Europe Chronic Pancreatitis (CP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Chronic Pancreatitis (CP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Chronic Pancreatitis (CP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chronic Pancreatitis (CP) Market

• 16.1. UK Chronic Pancreatitis (CP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Chronic Pancreatitis (CP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Chronic Pancreatitis (CP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chronic Pancreatitis (CP) Market

• 17.1. Germany Chronic Pancreatitis (CP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Chronic Pancreatitis (CP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Chronic Pancreatitis (CP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chronic Pancreatitis (CP) Market

• 18.1. France Chronic Pancreatitis (CP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Chronic Pancreatitis (CP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Chronic Pancreatitis (CP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chronic Pancreatitis (CP) Market

• 19.1. Italy Chronic Pancreatitis (CP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Chronic Pancreatitis (CP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Chronic Pancreatitis (CP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chronic Pancreatitis (CP) Market

• 20.1. Spain Chronic Pancreatitis (CP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Chronic Pancreatitis (CP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Chronic Pancreatitis (CP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chronic Pancreatitis (CP) Market

• 21.1. Eastern Europe Chronic Pancreatitis (CP) Market Overview
• 21.2. Eastern Europe Chronic Pancreatitis (CP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Chronic Pancreatitis (CP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Chronic Pancreatitis (CP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chronic Pancreatitis (CP) Market

• 22.1. Russia Chronic Pancreatitis (CP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Chronic Pancreatitis (CP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Chronic Pancreatitis (CP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chronic Pancreatitis (CP) Market

• 23.1. North America Chronic Pancreatitis (CP) Market Overview
• 23.2. North America Chronic Pancreatitis (CP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Chronic Pancreatitis (CP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Chronic Pancreatitis (CP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chronic Pancreatitis (CP) Market

• 24.1. USA Chronic Pancreatitis (CP) Market Overview
• 24.2. USA Chronic Pancreatitis (CP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Chronic Pancreatitis (CP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Chronic Pancreatitis (CP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chronic Pancreatitis (CP) Market

• 25.1. Canada Chronic Pancreatitis (CP) Market Overview
• 25.2. Canada Chronic Pancreatitis (CP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Chronic Pancreatitis (CP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Chronic Pancreatitis (CP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chronic Pancreatitis (CP) Market

• 26.1. South America Chronic Pancreatitis (CP) Market Overview
• 26.2. South America Chronic Pancreatitis (CP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Chronic Pancreatitis (CP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Chronic Pancreatitis (CP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chronic Pancreatitis (CP) Market

• 27.1. Brazil Chronic Pancreatitis (CP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Chronic Pancreatitis (CP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Chronic Pancreatitis (CP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chronic Pancreatitis (CP) Market

• 28.1. Middle East Chronic Pancreatitis (CP) Market Overview
• 28.2. Middle East Chronic Pancreatitis (CP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Chronic Pancreatitis (CP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Chronic Pancreatitis (CP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chronic Pancreatitis (CP) Market

• 29.1. Africa Chronic Pancreatitis (CP) Market Overview
• 29.2. Africa Chronic Pancreatitis (CP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Chronic Pancreatitis (CP) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Chronic Pancreatitis (CP) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chronic Pancreatitis (CP) Market Competitive Landscape And Company Profiles

• 30.1. Chronic Pancreatitis (CP) Market Competitive Landscape
• 30.2. Chronic Pancreatitis (CP) Market Company Profiles
  • 30.2.1. Pfizer Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi Overview, Products and Services, Strategy and Financial Analysis

31. Chronic Pancreatitis (CP) Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb
• 31.2. Abbott Laboratories
• 31.3. Novartis AG
• 31.4. GlaxoSmithKline plc
• 31.5. Baxter
• 31.6. CSL Behring
• 31.7. Octapharma AG
• 31.8. Dr. Reddy's Laboratories
• 31.9. Nestle Health Science
• 31.10. Cerata Pharmaceuticals
• 31.11. Unichem Laboratories Ltd
• 31.12. LGM Pharma
• 31.13. Aptalis Pharmaceutical Technologies
• 31.14. Digestive Care Inc
• 31.15. Akron Biotech

32. Global Chronic Pancreatitis (CP) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chronic Pancreatitis (CP) Market

34. Recent Developments In The Chronic Pancreatitis (CP) Market

35. Chronic Pancreatitis (CP) Market High Potential Countries, Segments and Strategies

• 35.1 Chronic Pancreatitis (CP) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Chronic Pancreatitis (CP) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Chronic Pancreatitis (CP) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer